TN2013000322A1 - Pharmaceutical compositions comprising human antibodies to pcsk9 - Google Patents
Pharmaceutical compositions comprising human antibodies to pcsk9Info
- Publication number
- TN2013000322A1 TN2013000322A1 TNP2013000322A TN2013000322A TN2013000322A1 TN 2013000322 A1 TN2013000322 A1 TN 2013000322A1 TN P2013000322 A TNP2013000322 A TN P2013000322A TN 2013000322 A TN2013000322 A TN 2013000322A TN 2013000322 A1 TN2013000322 A1 TN 2013000322A1
- Authority
- TN
- Tunisia
- Prior art keywords
- pcsk9
- antigen
- present
- antibodies
- binding fragments
- Prior art date
Links
Abstract
The present invention relates to Pharmaceutical compositions comprising an antibody specifically binding to human proprotein convertase subtilisin/kexin type 9 (PCSK9), to methods for treating diseases or conditions in which proprotein convertase subtilisin/kexin type 9 (PCSK9) expression or activity causes an impact by administration of PCSK9-specific antibodies or antigen-binding fragments thereof and preferably by additional administration of an inhibitor of 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMG-CoA reductase). The present invention further relates to PCSK9-specific antibodies or antigen-binding fragments thereof for use in the treatment of diseases or conditions in which PCSK9 expression or activity causes an impact. The present invention also relates to articles of manufacture comprising packaging material, PCSK9-specific antibodies or antigen-binding fragments thereof, and a label or packaging insert indicating which groups of patients can be treated with said antibodies or fragments, which groups of patients must not be treated with said antibodies or fragments, and which dosage regimen should be used. The present invention further relates to methods of testing the efficacy of PCSK9-specific antibodies or antigen-binding fragments thereof for the treatment of certain diseases or conditions and for the treatment of specific sub-groups of patients.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11306450 | 2011-11-08 | ||
PCT/EP2012/051321 WO2012101253A1 (en) | 2011-01-28 | 2012-01-27 | Pharmaceutical compositions comprising human antibodies to pcsk9 |
Publications (1)
Publication Number | Publication Date |
---|---|
TN2013000322A1 true TN2013000322A1 (en) | 2015-01-20 |
Family
ID=54337507
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TNP2013000322A TN2013000322A1 (en) | 2011-11-08 | 2013-07-26 | Pharmaceutical compositions comprising human antibodies to pcsk9 |
Country Status (1)
Country | Link |
---|---|
TN (1) | TN2013000322A1 (en) |
-
2013
- 2013-07-26 TN TNP2013000322A patent/TN2013000322A1/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12021500018A1 (en) | Human antibodies to pcsk9 for use in methods of treating particular groups of subjects | |
AR124482A2 (en) | PHARMACEUTICAL COMPOSITIONS INCLUDING HUMAN ANTIBODIES AGAINST PCSK9 | |
BR112014005799A2 (en) | antibodies to pcsk9, their uses, and pharmaceutical composition | |
MY170089A (en) | Methods for reducing lipoproten(a) levels by administering an inhibitor of proprotein convertase subtilisin kexin-9 (pcsk9) | |
MX2016006226A (en) | Dosing regimens for use with pcsk9 inhibitors. | |
MX2014001372A (en) | Pharmaceutical composition for treatment and/or prevention of pancreatic cancer. | |
EA201490378A1 (en) | TREATMENT OF MULTIPLE SCLEROSIS USING THE COMBINATION OF LACHINIMODA AND INTERFERON-β | |
NZ606988A (en) | Combination pharmaceutical compositions and method of treatment of vertigo, kinetosis and vegetative-vascular dystonia | |
WO2015054619A3 (en) | Use of a pcsk9 inhibitor to treat hyperlipidemia | |
NZ702315A (en) | Methods and uses for pro protein convertase subtilisin kexin 9 (pcsk9) inhibitors | |
EA201490653A1 (en) | DERIVATIVES ESTRA-1,3,5 (10), 16-TETRAEN-3-CARBOXAMIDE, METHOD FOR THEIR PRODUCTION CONTAINING THEIR PHARMACEUTICAL PREPARATIONS | |
EA201400002A1 (en) | METHODS TO TREAT DISEASES OF THE RETAIL | |
NZ606969A (en) | A method of treating alzheimer’s disease | |
TN2013000322A1 (en) | Pharmaceutical compositions comprising human antibodies to pcsk9 | |
MX2013002503A (en) | Combination of hdac inhibitors with thrombocytopenia drugs. | |
EA200801854A1 (en) | NEW COMPOSITIONS | |
TH177074A (en) | Antibody human antibodies against PCSK9 for use in the treatment of specific patient groups. | |
UA56025U (en) | Method for determination of illegal drugs and drastic medicinal agents in human biological material | |
EA201201226A1 (en) | SOLID MEDICINE FORM, possessing an anorexigenic action (OPTIONS) |